

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/136669 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) *A61P 37/06* (2006.01)
C07K 16/24 (2006.01) *A61P 37/08* (2006.01)
C07K 16/28 (2006.01) *A61P 29/00* (2006.01)
A61K 39/395 (2006.01) *A61P 17/04* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/087561

(22) International Filing Date:

23 December 2021 (23.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20216957.9 23 December 2020 (23.12.2020) EP

(71) Applicant: **NUMAB THERAPEUTICS AG** [CH/CH];
Einsiedlerstrasse 34, 8820 Wädenswil (CH).

(72) Inventors: **TIETZ, Julia**; Bundentalstrasse 1, 8952 Schlieren (CH). **GUNDE, Tea**; Turbinenstrasse 33, 8005 Zurich (CH). **JOHANSSON, Maria**; Route du Lac 7, 1026 Denges (CH). **WARMUTH, Stefan**; Zopfstrasse 28, 8804 Au (CH). **SIMONIN, Alexandre**; 5 rue de l'Au, 68128 Rosenau (FR). **HESS, Christian**; Uetlibergstrasse 304, 8045 Zurich (CH). **SHIRAISHI, Noriko**; c/o KAKEN PHARMACEUTICAL CO., LTD., 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, 113-8650 (JP). **ARAKAWA, Yoshio**; c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiya, Minamikawara-cho, Yamashina-ku, Kyoto, 607-8042 (JP). **MIYAKE, Yoshiohide**; c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiya, Minamikawara-cho, Yamashina-ku, Kyoto, 607-8042 (JP).

(74) Agent: **WALLINGER RICKER SCHLOTTER TOST-MANN**; Dr. Bernhard Virnekäs, Patent- und Rechtsanwälte, Partnerschaft mbB, Zweibrückenstraße 5-7, 80331 Munich (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR IL-4R AND IL-31

(57) Abstract: The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to IL-4R (IL4R-BDs), and one or two binding domains, which specifically bind to IL-31 (IL31-BDs), wherein the multispecific antibody comprises an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

WO 2022/136669 A1